The Motley Fool Podcasts Industry Focus Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis

Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis Logo

Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis

The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.

Check out more of our content here:

Listen to Healthcare: A Breach of Trust? Why The FDA's Taking Aim At Novartis' AveXis

Recent Episodes

Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen

More Podcasts